Spyre Therapeutics Inc. (SYRE) - Total Assets
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) holds total assets worth $1.17 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Spyre Therapeutics Inc. - Total Assets Trend (2013–2025)
This chart illustrates how Spyre Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Spyre Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
Spyre Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Spyre Therapeutics Inc.'s total assets of $1.17 Billion consist of 100.0% current assets and 0.0% non-current assets. Review SYRE current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Spyre Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Spyre Therapeutics Inc. (SYRE) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spyre Therapeutics Inc.'s current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Spyre Therapeutics Inc. Competitors by Total Assets
Key competitors of Spyre Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Spyre Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.53 | 6.49 | 5.75 |
| Quick Ratio | 18.53 | 6.49 | 5.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.11 Billion | $455.77 Million | $97.09 Million |
Spyre Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Spyre Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.72 |
| Latest Market Cap to Assets Ratio | 10.34 |
| Asset Growth Rate (YoY) | 27.8% |
| Total Assets | $777.78 Million |
| Market Capitalization | $8.04 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Spyre Therapeutics Inc.'s assets at a significant premium (10.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Spyre Therapeutics Inc.'s assets grew by 27.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Spyre Therapeutics Inc. (2013–2025)
The table below shows the annual total assets of Spyre Therapeutics Inc. from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $777.78 Million | +27.82% |
| 2024-12-31 | $608.48 Million | +77.99% |
| 2023-12-31 | $341.86 Million | +380.52% |
| 2022-12-31 | $71.14 Million | -35.28% |
| 2021-12-31 | $109.93 Million | -31.98% |
| 2020-12-31 | $161.62 Million | +94.29% |
| 2019-12-31 | $83.18 Million | +7.00% |
| 2018-12-31 | $77.74 Million | +38.63% |
| 2017-12-31 | $56.08 Million | -16.38% |
| 2016-12-31 | $67.06 Million | +73.50% |
| 2015-12-31 | $38.65 Million | +1219.25% |
| 2014-12-31 | $2.93 Million | -36.26% |
| 2013-12-31 | $4.60 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more